EUCTR2010-024061-48-BG进行中（未招募）不适用
Phase II, open-label study of erlotinib (Tarceva®) treatment in patients with locally advanced, metastatic or recurrent non-small cell lung cancer who present activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor - n/a
Roche Bulgaria EOOD0 个研究点开始时间: 2011年2月22日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients able and willing to give written informed consent. Consent must be obtained prior to any study-specific procedure.
- •2.Histologically documented inoperable, locally advanced (stage IIIB with supraclavicular lymph node metastases or malignant pleural or pericardial effusion (if clinically significant – after treatment)) or metastatic (stage IV) or recurrent NSCLC disease who present activating mutations (exon 19 deletions or exon 21 substitution L858R) in the tyrosine kinase domain of EGFR.
- •3.At least one measurable leasion must be characterized according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
- •4.Male or female patients aged = 18 years.
- •5.Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- •6.Life expectancy = 12 weeks.
- •7.Adequate hematological function: Absolute neutrophil count (ANC) = 1.5 x 109/L, and Platelet count = 100 x 109/L, and Hemoglobin = 9 g/dL (may be transfused to maintain or exceed this level).
- •8.Adequate liver function: Total bilirubin < 1.5 x upper limit of normal (ULN), and aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT) < 2.5 x ULN in patients without liver metastases; < 5 x ULN in patients with liver metastases.
- •9.Adequate renal function: Serum creatinine = 1.25 x ULN, Creatinine clearance = 60 ml/min.
- •10.Able to comply with the required protocol and follow-up procedures, and able to receive oral medications.
- •11.Female patients must be postmenopausal (24 months of amenorrhea), surgically sterile or they must agree to use a physical method of contraception. Male patients must be surgically sterile or agree to use a barrier method of contraception. Women with an intact uterus (unless amenorrhoeic for the last 24 months) must have a negative pregnancy test (urine or serum) within 3 days prior to enrolment into the study. Male and female patients must use effective contraception during the study and for a period of 60 days following the last administration of erlotinib. Acceptable methods of contraception include an established hormonal therapy or intrauterine device for females, and the use of a barrier contraceptive (i.e. diaphragm or condoms) with spermicide.
- •12.Patients with stable cerebral metastases who have received surgical or radio therapy will be eligible for the study. Those patients may have received radiation therapy for their cerebral metastases before the initiation of systemic treatment for non-small-cell lung cancer also will be eligible.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Previous treatment with chemotherapy or therapy against EGFR, either with antibody or small molecule (tyrosine kinase inhibitor) for metastatic disease. The administration of neoadjuvant or adjuvant therapy after radical surgery is allowed as long as it has finalized ? 6 months before entering the study. Patients can have received radiotherapy as long as the irradiated lesion is not the only target lesion for evaluating response and as long as radiotherapy has been completed before initiating the study treatment (a 2-week period is recommended).
- •2.Treatment with an investigational drug agent during the 3 weeks before enrollment in the study.
- •3.History of another neoplasm other than carcinoma in situ of the uterine cervix, basal cell skin carcinoma treated adequately, or prostate carcinoma with a good prognosis (Gleason ? 6) treated radically. History of another neoplasm treated curatively and without evidence of disease in the last 5 years.
- •4.Patients with symptomatic cerebral metastases.
- •5.Known hypersensitivity to any of excipients of erlotinib.
- •6.Any significant ophthalmologic abnormality, especially severe dry eye syndrome, keratoconjunctivitis sicca, Sjögrens syndrome, severe exposure keratitis or any other disorder likely to increase the risk of corneal epithelial lesions. The use of contact lenses is not recommended during the study. The decision to continue to wear contact lenses should be discussed with the patient’s treating oncologist and the ophthalmologist.
- •7.Coumarins (CoumadinTM; warfarin) use. If the patient requires anti-coagulation therapy, the use of low molecular weight heparin instead of coumarins is recommended where clinically possible.
- •8.Unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).
- •9.Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications.
- •10.Positive urine or serum pregnancy test in women of childbearing potential. Patients (male or female) with reproductive potential not willing to use effective method of contraception. Female patients should not be pregnant or breast-feeding. Oral or injectable contraceptive agents cannot be the sole method of contraception.
- •11.Patients with pre-existing parenchymal lung disease such as pulmonary fibrosis, lymphangiosis and carcinomatosis (if this is the only presence of the disease).
- •12.Patients with known infection with HIV, HBV, HCV. Testing is not required in the absence of clinical signs and symptoms suggestive of these conditions.
- •13.Patients assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
- •14.Incapacity to take oral medication or previous surgical procedures that affect absorption and imply the need for intravenous or parenteral feeding.
研究者
相似试验
进行中（未招募）
1 期
Phase II, open-label study of erlotinib (Tarceva®) treatment in patients with locally advanced or metastatic non-small cell lung cancer who present activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor. - MuTARPatients with histologically or cytologically confirmed locally advanced or metastatic NSCLC who have not received previous chemotherapy for their disease and who present activating mutations in the TK domain of the EGFR.Any patient with locally advanced or metastatic non-small cell lung cancer disease found to have an EGFR Exon 19 deletion or exon 21 substitution L858R in the TK domain of EGFR gene will be offered first-line treatment with erlotinib.EUCTR2010-022509-17-PTRoche Farmacêutica Química, Lda30
进行中（未招募）
1 期
Phase II, open-label study of erlotinib (Tarceva) treatment In patients with locally advanced or metastatic non-small-cell lung cancer who present activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) - TRIGGERStage IIIB, IV non-small-cell lung cancer (NSCLC)MedDRA version: 9.1Level: LLTClassification code 10029521MedDRA version: 9.1Level: LLTClassification code 10025054EUCTR2010-023892-24-ITROCHE
进行中（未招募）
不适用
A randomized phase II trial of erlotinib (TARCEVA) or intermittent dosing of erlotinib and docetaxel in male former smokers with locally advanced or metastatic squamous nonsmall cell lung cancer (NSCLC) in second-line setting after failure on chemotherapy. - TalismaEUCTR2010-020229-42-ITROCHE
招募中
不适用
Three drug combination chemotherapy in previously untreated patients with locally advanced unresectable or metastatic Pancreatic CancerDiseases of the digestive systemKCT0000137Soon Chun Hyang University Hospital Bucheon32
进行中（未招募）
1 期
A Phase 2 Randomized Study of Tarceva® (erlotinib) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Newly Diagnosed Advanced Non-Small Cell Lung Cancer who have Tumors with EGFR Protein Overexpression and/or Increased EGFR Gene Copy Numberson-small Cell Lung CancerMedDRA version: 9.1 Level: LLT Classification code 10061873 Term: Non-small cell lung cancerEUCTR2006-005905-79-GBOSI Pharmaceuticals, Inc.140